The rough streets of Pok. That made me laugh.

Looking forward to the "we have started ph3" PR ...come on any day Celia?
Glta

Well written captain Vid

I think we all agree that the risks are still there. its biotech. even after FDA approval a drug is still at risk of being pulled from the market (Pona style). I just more of an optimist in my investment strategy as opposed to BR. Nothing wrong with his/her slant on investing. 'To each his own'

Looking at the brighter side is how I roll.

You cleverly withheld that the world called ariad a "Me-too" pertaining to NSCLC. and look at the premium received. If you don't like the science updates behind Voclosporin serving an empty competitive field perhaps you could look into other biotech opportunities like an potential FDA approved ALS drug...oh wait that just happened too. :)

Nice and very interesting events . Have a good weekend Dew

Interesting that the PDUFA date wasn't due until 6/16/17 and that the FDA asked them to apply for approval

FDA just approved Radicava (edaravone) for ALS, marketed by Mitsubishi Tanabe Pharma America. Company says price will be $145,000 per year.-per M herper Twitter

tick tock kids.

Takeda unphased by Bernie Sanders' campaign against Ariad...Alunbrig pricing detailed

"The drug, which also acts against lung cancer that spreads to the brain, carries a list price of $14,250 for a 30-day supply. That amounts to more than $170,000 a year."

https://www.bostonglobe.com/business/2017/04/28/takeda-lung-cancer-drug-for-sale/JjMMbUo9DYmw25rHzCKKVJ/story.html

great post Awlau.

Now that was a great call. Great job Nick restoring faith in the long play game plan

hahaha. I hate when that happens

I thought I was the only one with that % of the company ;)

the social media company run by Jack

Brigatinib approved!

https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm555841.htm

Excellent!

Novartis--
The U.S. Food and Drug Administration today approved Rydapt (midostaurin) for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML)
https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm555778.htm

Bayer
The U.S. Food and Drug Administration today expanded the approved use of Stivarga (regorafinib) to include treatment of patients with hepatocellular carcinoma (HCC or liver cancer) who have been previously treated with the drug sorafenib
https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm555608.htm

BMRN
The U.S. Food and Drug Administration today approved Brineura (cerliponase alfa) as a treatment for a specific form of Batten disease

https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm555613.htm

Ariad-Takeda: I say we here Brigatinib's FDA approval decision after hours today through tomorrow

FDA- Illegally sold cancer Treatment Warning letters issued

https://www.fda.gov/ForConsumers/ProtectYourself/HealthFraud/ucm533465.htm#T1

I bet your wife thought the new beach house was definitely the right call! enjoy

hahaha
funny Vid

Thanks for your response. I didn't invest in Ariad thinking a buyout was guaranteed. I didn't rule it out though. I was more interested in the fact that in Autumn 2013 the FDA decided to temporarily pull Pona from the market instead of ban it. At that point Sarissa Capital had made its position and case and it was evident that Ariad had a probability of recovery. I was really impressed with the early Brigatinib data as well. I was actually more bullish on the company because of Brig than most considering that the focus was Pona. I looked at a buyout as a possibility with a recovery given the pipeline strength more likely an outcome.

I don't see a quicker-than-normal approval process for Voclosporin. I see a normal process which the company now has full funding for after the recent offering. I find that the company management's goal is to sell to the highest bidder as the leadership is stacked with Merger and Acquisition talent.. That is my personal opinion. The magic question is when? What is Glickman's timeline? He definitely is calling the shots. If Voclosporin gets into late phase 3 with the FDA assigning a PDUFA date I will be surprised IMO
If that doesn't happen then the company has solid science and the funds to continue which Ariad did not

you are correct. we could hear about Brig any day. 4/29/17 was the FDA deadline

I woke up as I usually do between 4-5am est made a cup of coffee (it was horrible--at the time I had a cheap Mr Coffee). around 7am ARIA hit the Trade Halt Alert List. I immediately became more interested in that than my cup of sludge. A quick search on Twitter revealed the reason for the Halt. A Biotech guy I respect posted "Takeda buys Ariad $24". At this point I went to Adam Feuerstein's Twitter page and politely informed him that he was dead wrong on Ariad Pharma as he had recently published his 2016 year in review Street writeup... interestingly he immediately responded publicly that he was in fact wrong about Ariad.

after that I was very happy for the rest of the day and showed my wife my cell phone which read ARIA $23.97...trust me she heard plenty about the company :)

There is a faction on another public forum site who are bent on the idea that there are no catalysts left for AUPH until the end of the phase 3 trial in a few years. thats incorrect as we have learned from other companies like ARIA...remember when Ariad brought on a women by the name Ms Soni to the board? She had expertise in biotech deals and used to work at Takeda (shocking) I remember the stock really started to move after that appointment. It wasn't some overnight burst but an upward trend and higher daily volume along with excitement about Brig and expanded Pona development. My point is that turned out to be a catalyst that wasn't surrounding a science conference or announcement. We can expect plenty of events to occur with AUPH. Lets face the facts, AUPH has fantastic science and very recent findings. no competition out there, and a management team experienced with execution,deals,and buyouts

If folks think these gents are sitting around picking their noses bored waiting for the next results on Voclosporin. you are greatly mistaken.

So the AUPH Board of Directors is dripping with Merger and Acquisition talent. lets review as its pretty hilarious how obvious this company is for sale

We all know the first--> Richard Glickman. He needs no introduction for folks like us who listen into the webcasts. This dude knows the business and is well aware of the position he has the company in at this point. Former Founder and CEO of Aspreva Pharma who developed CellCept- the current standard of care for Lupus Nephritis. Aspreva Pharma was acquired by Galenica in 2008.

We have Lorin "Jeff" Randall with over 30 years experiences with biotech financials, he has "led a number of companies through multi-million dollar financings, mergers and acquisitions

There's Gregory Ayers MD PhD who was a venture partner for MPM Capital when he founded CryoCor (NASDAQNM:CRYO)...CryoCor was bought by Boston Scientific in 2007. He served on the Board of Hemosense which was bought by Inverness Medical and prior to all of this he was VP of clinical affairs for INcontrol which was bought by Guidant in the late 90's.

Don't forget Dr David Jayne who appears to be a world authority on all things lupus as well as a medical advisor to the UK, US, and EU Regulatory Bodies from a certified nephrology standpoint...

Then we have the final two recent appointments which are really exciting! lets see...

There's Hyuek Joon Lee Phd- this dude knows what he is doing for sure. Currently he is Director of New Business Development for ILJIN group. (we know who they are!) For ILJIN he is "responsible for mergers and acquisitions and managing overseas investments, joint ventures and subsidiaries."

Finally we have Ben Rovinski Phd. He's one of my favorites. why? well he is an ole chap from Lumira Capital. (we know who they are). Glick is a partner at Lumira as well. Ben has an investment focus on mid-to-late stage life science companies. "His current and past board roles and investment responsibilities include several companies, including KAI Pharma (acquired by AMGEN); Morphotek (acquired by Eisai); Health Hero Network (acquired by Bosch); Avalon Pharma (acquired by Clinical Data inc); SGX Pharma (acquired by Eli Lilly). among other companies. this guy has made deals after deals after deals after deals


When you doubt your investment just re-read my synopsis here and ask yourself how many times I had to type " bought by" or "acquired by"

I can tell you this, this Board was assembled for a reason folks

9 hours of daily dialysis. now that is intense. I appreciated her remarks about dealing with this condition on a daily basis. tonights presentation was the best yet

I agree 100% with these remarks. why should today go parabolic? Its the AURA-LV 2b 48 week data, which we already were presented with the awesome results. The clinicians presenting will elaborate on already public info. Don't get me wrong, I'm excited to tune in tonight for the presentation.

I just don't understand the folks who are expecting a double digit move from a review of science progress today.

Any big announcements are the exception. If they have partner plans to announce or relevant, then lets go parabolic!

U.S. FDA Issues Complete Response Letter for Baricitinib
Eli Lilly and Company (NYSE:LLY) and Incyte Corporation (NASDAQ:INCY) announced today that the U.S. Food and Drug Administration (FDA) has issued a complete response letter for the New Drug Application (NDA) of the investigational medicine baricitinib, a once-daily oral medication for the treatment of moderate-to-severe rheumatoid arthritis (RA).

http://www.businesswire.com/news/home/20170414005051/en/U.S.-FDA-Issues-Complete-Response-Letter-Baricitinib

awesome. I'm in. we can continue onward to whistler backcomb while we are up there. incredible place. have a great holiday folks

I'm 38 live in Pittsburgh with a fine wife a 3 year old and a newborn. Count me in on the Caribbean party Aurinia is a gem. You can find me in Costa Rica after the windfall

What's up 2da!

Haha. My wife knows all about brig too. Lol

Well put john.

Sleep tight john Mackey

Aurinia Pharmaceuticals Inc.,today announced that it will host an Investor Event during the National Kidney Foundation Spring Clinical Meeting on April 20, 2017 at 6:00pm Eastern Time in Orlando, FL.

http://ir.auriniapharma.com/press-releases/detail/83

This was PR'd on 4/06/17 and not related to voclosporin however is an example of big Pharma scooping up a promising ph3 ready candidate based on strong ph2 data based on an unmet medical need. the competition is crowded in dry eye whereas AUPH is not.
https://www.novartis.com/news/media-releases/novartis-strengthen-rd-pipeline-licensing-ecf843-ophthalmic-indications

awesome. As BR states if we are all so lucky with a premium buyout as the end result I'll be tickled. However, as you would agree, I'm also as eagerly awaiting the other exciting catalysts for this company and science. Lets hear from the Kidney Conference! Japan! Partner deals, GLTA

yes. don't get too sick we have a great investment here. nothing but excellent news from the science and management. A lot of folks simply making noise about what will happen tomorrow or at 1 pm or what some doucher on ST claims from his "expert-always-perfect" day trading posts. lol. its all about the long run which is huge based on my DD. GLTA